Fjeldbo CS, Bakke I, Erlandsen SE, Holmseth J, Laegreid A, Sandvik AK, Thommesen L, Bruland T. Gastrin upregulates the prosurvival factor secretory clusterin in adenocarcinoma cells and in oxyntic mucosa of hypergastrinemic rats. Am J Physiol Gastrointest Liver Physiol 302: G21-G33, 2012. First published October 13, 2011 doi:10.1152/ajpgi.00197.2011We show that the gastric hormone gastrin induces the expression of the prosurvival secretory clusterin (sCLU) in rat adenocarcinoma cells. Clusterin mRNA was still upregulated in the presence of the protein synthesis inhibitor cycloheximide, although at a lower level. This indicates that gastrin induces clusterin transcription independently of de novo protein synthesis but requires de novo protein synthesis of signal transduction pathway components to achieve maximal expression level. Luciferase reporter assay indicates that the AP-1 transcription factor complex is involved in gastrin-mediated activation of the clusterin promoter. Gastrininduced clusterin expression and subsequent secretion is dependent on sustained treatment, because removal of gastrin after 1-2 h abolished the response. Neutralization of secreted clusterin by a specific antibody abolished the antiapoptotic effect of gastrin on serum starvationinduced apoptosis, suggesting that extracellular clusterin is involved in gastrin-mediated inhibition of apoptosis. The clusterin response to gastrin was validated in vivo in hypergastrinemic rats, showing increased clusterin expression in the oxyntic mucosa, as well as higher levels of clusterin in plasma. In normal rat oxyntic mucosa, clusterin protein was strongly expressed in chromogranin A-immunoreactive neuroendocrine cells, of which the main cell type was the histidine decarboxylase-immunoreactive enterochromaffin-like (ECL) cell. The association of clusterin with neuroendocrine differentiation was further confirmed in human gastric ECL carcinoids. Interestingly, in hypergastrinemic rats, clusterin-immunoreactive cells formed distinct groups of diverse cells at the base of many glands. Our results suggest that clusterin may contribute to gastrin's growth-promoting effect on the oxyntic mucosa. apoptosis; AR42J cells; reverse transfection; neuroendocrine cells; carcinoids THE PEPTIDE HORMONE GASTRIN is important in maintenance of architecture and function of the acid-secreting (oxyntic) mucosa of the stomach. It is a well-recognized regulator of gastric acid secretion and exerts a general growth-promoting effect on the gastric mucosa. Prolonged elevated plasma gastrin levels (hypergastrinemia), particularly in conjunction with inflammation, may play a role in gastrointestinal carcinogenesis (12, 13, 60) . The gastric mucosa is under constant renewal, and both proliferation and apoptosis are important components for maintaining homeostasis (21, 46). Although most research has concentrated on gastrin's proliferation-inducing effect (30), recent evidence suggests that it is also a potent inhibitor of cellular apoptosis (33, 45, 47, 54, 56) . Thus both stimulation of proliferation and inhibition of apoptosis may be central mechanisms involved in the growth-promoting effect of gastrin.
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Genomewide gene expression time series experiments represent a valuable approach for studying a cell's response to a given stimulus, since they reveal the dynamics of the response over time (3) . We found clusterin mRNA to be highly upregulated by gastrin in several 14-to 24-h microarray time series experiments in the rat adenocarcinoma-derived cell line AR42J (E-MTAB-123 and GSE32869). Clusterin has been associated with biological processes like proliferation, cell survival, and cell death (48, 51) . Several clusterin protein forms with different subcellular and extracellular locations have been described. The most abundant and best documented protein form is secretory clusterin (sCLU), found ubiquitously expressed in most tissues and biological fluids. sCLU is a 75-to 80-kDa heterodimeric glycoprotein consisting of two chains (ϳ40 kDa each) linked together through five disulfide bonds. Its uncleaved intracytoplasmic precursor (preCLU) has an apparent size of ϳ60 kDa by Western blot analysis. sCLU is described as an extracellular chaperone and is a prosurvival, cytoprotective protein (32, 48, 51, 61) . In addition, functional clusterin protein forms have been described in both the nucleus and cytoplasm. The presence of a 45-to 55-kDa clusterin form in the nucleus (nCLU) is associated with cell death (37, 64) , whereas clusterin in the cytoplasm is associated with cell survival (58) . The origin of these intracellular clusterin protein forms is still unknown, although various mechanisms have been proposed to explain their presence (as reviewed in Ref. 48 ).
Since clusterin is involved in biological processes linked to regulation of growth and survival, and experiments have shown that clusterin is a gastrin-responsive gene, we hypothesized that clusterin can be an important factor in the antiapoptotic action of gastrin in the gastric mucosa. In the present study, we have therefore examined the gastrin-induced upregulation of clusterin in adenocarcinoma AR42J cells in relation to apoptosis and validated the clusterin response to gastrin in an in vivo model using hypergastrinemic rats.
MATERIALS AND METHODS
Cells, reagents, plasmids, and antibodies. Unless otherwise stated, the AR42J cells (rat pancreatic acinar cell derived, ATCC, Rockville, MD) were cultured at 37°C in a humidified 5% CO 2 incubator in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose (GIBCO, Invitrogen, Carlsbad, CA) supplemented with 1% (vol/vol) penicillin-streptomycin (GIBCO, Invitrogen), 0.1 mg/ml L-glutamine (GIBCO, Invitrogen), 1 g/ml fungizone (GIBCO, Invitrogen), 1 mM sodium pyruvate (GIBCO, Invitrogen), and 15% fetal bovine serum (FBS, Lonza BioWhittaker, Basel, Switzerland). Gastrin-17 and cycloheximide (CHX) were purchased from Sigma-Aldrich (St. Louis, MO). The luciferase reporter plasmids pRAL and pRAL-AP(Ϫ), with the Firefly luciferase gene driven by the rat clusterin 5=-regulatory region from ϩ57 to Ϫ1297, with the activator protein-1 (AP-1) binding site deleted in pRAL-AP(Ϫ), was kindly provided by Professor Howe (26) . A control plasmid with a minimal TATA promoter (pTA-Luc) was obtained from Panomics (Fremont, CA), and phRL-Null was obtained from Promega (Madison, WI). The following antibodies were used: polyclonal (goat) anti-human clusterin-␣ (reacts with mouse, rat, and human) (C-18, sc-6419, Santa Cruz Biotechnology, Santa Cruz, CA); polyclonal (rabbit) anti-human clusterin (reacts with mouse, rat, and human) (H330, sc-8354, Santa Cruz Biotechnology); monoclonal (mouse) anti-human ␣-tubulin (reacts with mouse, rat, and human) (sc-5286, Santa Cruz Biotechnology); polyclonal (rabbit) anti-porcine chromogranin A (CgA) (reacts with rat and mouse) (20086, ImmunoStar, Hudson, WI); monoclonal (mouse) anti-human CgA (M0869, DAKO, Glostrup, Denmark); polyclonal (rabbit) anti-histidine decarboxylase (HDC) (B260 -1; Eurodiagnostics, Malmö, Sweden); polyclonal horseradish peroxidase (HRP)-conjugated (rabbit) anti-goat (ab6741, Abcam, Cambridge, UK); polyclonal HRP-conjugated (goat) anti-mouse (PO447, DAKO); Alexa Fluor 488 (donkey) anti-goat (A11055, Invitrogen), rabbit polyclonal IgG (ab27478, Abcam); goat IgG (I-5000, Vector Laboratories, Burlingame, CA); rabbit/mouse EnVision-HRP, and DABϩ kit (K5007, DAKO).
Animal study. The animal study was approved by the Animal Welfare Committee of the Faculty of Medicine, Norwegian University of Science and Technology, Norway. Female Sprague-Dawley rats (150 -200 g) (Taconic M&B, Skensved, Denmark) were housed in wire-bottom cages under standard conditions of 20°C, 40 -45% relative humidity, 12-h light-dark cycle and free access to commercial rat chow and water. The animals were weighed at start and weekly throughout the study. The proton pump inhibitor pantoprazole (Nycomed, Konstanz, Germany) (400 mol/kg body wt) was administered daily by gavage for either 1 or 4 wk to induce hypergastrinemia. Pantoprazole was suspended in Methocel (1 ml methylcellulose 2%, Sigma-Aldrich). The rats receiving pantoprazole for 1 wk were concomitantly subcutaneously injected with the gastrin/CCK-2 receptor antagonist YF476 (500 mol/kg body wt) {(R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2=-pyridyl)-1H-1, 4benzodiazepin-3-yl]-3-(3-methylamino-phenyl)urea} (donated by Ferring, Vanløse, Denmark) suspended in PEG300 (polyethylene glycol 300, Fluka Chemie, Switzerland), or PEG300 alone, at day 1. Methocel alone or Methocel and PEG300 alone were used as vehicle controls. Blood samples were taken from the femoral vein at the start of the study under isoflurane gas anesthesia (4%/2.5%) and from the inferior cava under anesthesia with 0.4 ml/100 g body wt of haloperidol (0.83 mg/ml), fentanyl (12.5 g/ml), and midazolam (1.25 mg/ml) at termination of the study. Immediately after final blood sampling, the stomachs were removed, opened, and rinsed in saline. Tissue samples of oxyntic mucosa were taken from similar location at the greater curvature and either fixed in 4% buffered formaldehyde for immunohistochemistry or immediately frozen in liquid nitrogen for mRNA and protein analysis. Plasma was frozen at Ϫ20°C.
Time series experiments in AR42J cells. AR42J cells were grown in six-well plates (3 ϫ10 5 cells/well in 2 ml DMEM containing 15% FBS) for 72 h. Then the growth medium was replenished with 2 ml serum-free DMEM, and the cells were serum starved for 20 -24 h before addition of gastrin (10 nM). Treated and untreated cells were grown in parallel and harvested (pool of 2-3 technical replicates) at several time points, as indicated in the figures. In experiments with the protein synthesis inhibitor CHX, pretreatments with CHX (10 g/ml)
were initiated 30 min before gastrin was added. In experiments with sustained vs. transient gastrin treatment, the growth medium of untreated and gastrin-treated cells was removed 1 h after gastrin addition, the cells were washed with serum-free medium and fresh serum-free medium with gastrin (sustained gastrin-treated cells) or without gastrin (transiently gastrin-treated or untreated cells) was added. The cells were harvested for RNA isolation or protein lysate (as described under RNA isolation and Western blot analysis).
RNA isolation. Total RNA from AR42J cells and frozen oxyntic samples was isolated by using RNeasy Mini kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. Approximately 20 mg oxyntic mucosal sample was homogenized in lysis buffer by use of an Ultra-Turrax rotating knife homogenizer, before RNA extraction with the RNeasy Mini Kit. RNA quantity and purity were assessed with a Nano Drop spectrophotometer (NanoDrop Technologies, Rockland, DE), and RNA integrity was controlled by measuring RNA integrity number (RIN) values via a Bioanalyzer capillary gel electrophoresis assay (Agilent Technologies, Palo Alto, CA). The RNA samples were kept at Ϫ80°C until further processing.
Genomewide gene expression time series experiments. Results from microarray time series analysis using AR42J cells are presented in this work. Detailed information about the microarray designs and raw data files from the experiments are accessible in ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/) by use of the accession numbers found in RESULTS or in the figure legends.
Real-time qRT-PCR. cDNA synthesis was performed using Transcriptor First Strand cDNA Synthesis Kit from Roche Diagnostics (Mannheim, Germany). For each reaction, 1,000 ng total RNA, 1 l oligo(dT), and nuclease-free water up to 13 l were mixed, heated for 10 min at 65°C, and put on ice to remove any secondary structures. Then 4 l reaction buffer (5ϫ), 0.5 l RNase inhibitor, 2 l dNTP mix, and 0.5 l reverse transcriptase were added to yield a total volume of 20 l. The reaction mixtures were incubated for 60 min at 50°C. To heat inactivate the enzyme, an incubation step for 5 min at 85°C was performed at the end. After the cDNA synthesis reaction, the samples were diluted 1:2 or 1:3 in sterile water. Quantitative RT-PCR (qRT-PCR) was performed by using Mx3000P Real-Time PCR System (Stratagene, San Diego, CA) and B-R SYBR Green SuperMix for iQ (Quanta Bioscience, Gaithersburg, MD). Each reaction contained SYBR Green SuperMix (2ϫ) (12.5 l), sense primer (2.5 l of 4 M), antisense primer (2.5 l of 4 M), cDNA template (2.5 l), and sterile water (5.0 l). Quantitative PCR thermal cycling program: 3 min at 95°C (enzyme activation), 40 thermal cycles of 15 s at 95°C (denaturation), 30 s at 60°C (annealing), and 40 s at 72°C (extension). A dissociation curve was made to confirm primer specificity. Design of PCR primers for rat clusterin was performed using Clone Manager 9 (Scientific & Educational Software, Cary, NC). The mRNA sequence was obtained by using the Ensemble Genome Browser (http://www.ensembl.org). Clusterin primers (Rattus norvegicus): sense 5=-gctccatagcccagctttac-3=[melting temperature (Tm) ϭ 62°C], antisense 5=-acttctcacactggcccttc-3= (Tm ϭ 63°C). Reference genes: ␤-actin sense 5=-ctggctcctagcaccatga-3=, antisense 5=-agccaccaatccacacaga-3= (53); B2m sense 5=-cgagaccgatgtatatgcttgc-3=, antisense 5=-gtccagatgattcagagctcca-3= (35) . All samples were run in triplicates for clusterin and reference gene, and relative mRNA expression levels were quantified by the ⌬⌬Ct method (38) . For analysis using AR42J cells, expression levels were calculated relative to untreated cells. For analysis using oxyntic mucosa samples, we made a control pool of RNA from all control samples and calculated expression levels relative to the expression level of the control pool.
Western blot analysis. To obtain protein extracts from AR42J cells, the cells were washed twice in PBS and harvested directly in 400 l cold RIPA buffer (Thermo Scientific, Rockford, IL) containing 8 l Halt Protease Inhibitor Single-Use Cocktail (100ϫ) (Thermo Scientific) and 4 l Halt Phosphatase Inhibitor Single-Use Cocktail (100ϫ) (Thermo Scientific) per well. The lysate was homogenized by use of a syringe and needle (21 G), and cell debris was removed by centrifugation (15 min, 14,000 g, 4°C). The supernatant was stored at Ϫ80°C until further processing. Protein extracts from rat oxyntic mucosa: 20 -30 mg oxyntic sample was homogenized in 350 l RIPA buffer supplemented with protease and phosphatase inhibitors as described for AR42J cells, by using an Ultra-Turrax rotating knife homogenizer. Cell debris was removed by centrifugation (15 min, 14,000 g, 4°C), and the supernatant was stored at Ϫ80°C.
The protein concentrations were measured by using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA) or Pierce BCA Protein Assay Kit (Thermo Scientific) according to the manufacturer's instructions. Gel electrophoresis and blotting were performed by using the NuPAGE system from Invitrogen according to the manufacturer's instructions. Samples (adjusted with double-distilled H 2O to equal amounts in g) were prepared for denaturing gel electrophoresis by adding NuPAGE LDS Sample Buffer (4ϫ) and NuPAGE Reducing Agent (10ϫ) to a total volume of 20 l and denatured for 10 min at 70°C. The samples were separated on a NuPAGE 10% Bis-Tris gel in 1ϫ NuPAGE MOPS SDS Running Buffer, and the proteins were transferred onto a 0.45-m polyvinylidene difluoride transfer membrane (Amersham Hybond-P, GE Healthcare, Buckinghamshire, UK). For detection of clusterin, the membranes were blocked in TBST (50 mM Tris·HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) with 5% bovine serum albumin (BSA) (Sigma-Aldrich) for 1 h at room temperature, incubated with the primary (goat) anti-human clusterin-␣ polyclonal antibody diluted 1:800 in TBST with 1% BSA overnight at 4°C, and incubated with the secondary HRP-conjugated (rabbit) anti-goat polyclonal antibody diluted 1:8,000 in TBST with 1% BSA for 2 h at room temperature. For detection of ␣-tubulin (loading control), blocking, washing, and antibody incubation were performed with SNAP i.d. Protein Detection System (Millipore, Billerica, MA) according to the manufacturer's instructions, using TBST with 1% BSA for blocking and antibody dilution. Antibodies: primary (mouse) anti-human ␣-tubulin monoclonal antibody diluted 1:300, secondary HRP-conjugated (goat) anti-mouse polyclonal antibody diluted 1:3,000. Binding of secondary antibodies was visualized by use of the SuperSignal West Femto Maximum Sensitive Substrate (Thermo Scientific) and Kodak Image Station 2000R (Kodak, Pittsburgh, PA). The band intensities were quantified by using Adobe Photoshop Elements 6.0, and clusterin intensities were normalized to ␣-tubulin intensities.
Analysis of clusterin concentration in conditioned medium and plasma. Conditioned medium from AR42J cells were collected immediately before harvesting the cells. Cells were removed by centrifugation (4,000 rpm, 5 min, 4°C), and the supernatant stored at Ϫ80°C. The clusterin protein level was quantified in conditioned medium and rat plasma by using Rat Clusterin ELISA kit from BioVendor Laboratorni Medicina AS (Modrice, Czech Republic) according to the manufacturer's descriptions.
Analysis of plasma gastrin concentration. Radioimmunoassay for plasma gastrin was performed as described previously (31) .
Reverse transfection and luciferase promoter-reporter assay. AR42J cells were transfected by a method based on the principles of transfected cell microarrays, where the cells are transfected in defined spots by printing a transfection mixture composed of the transfection reagent-nucleic acids complexes in a gelatin solution onto a glass slide prior to seeding the cells (16, 17, 66) . AR42J cells are difficult to transfect, but we observed high transfection efficiency on transfected cell microarrays (data not shown). To achieve high transfection efficiency in assays not compatible with the transfected cell microarray format (e.g., qRT-PCR, Western, luciferase assays), we optimized a protocol for transfecting the cells in a microtiter plate format by coating the wells with the transfection mixture prior to seeding the cells. We have previously seen that the sucrose concentration is important for the transfection efficiency (17) . Thus we optimized the sucrose concentration to achieve high transfection efficiency in the microtiter plate format and observed increasing transfection efficiency with increasing sucrose concentrations up to 200 mM (data not shown). This method yielded higher transfection efficiencies than traditional transient lipid-based transfection methods (data not shown). The transfection mixture containing 50 ng/l Firefly luciferase plasmid, 1 ng/l (1:50) Renilla luciferase plasmid as internal control, 200 mM sucrose, 3 l Metafectene PRO (Biontex Laboratories, Martinsried, Germany) per microgram plasmid, and 0.1% gelatin was added to the wells of a 96-well plate (4 l per well), spread evenly out, and air dried, before AR42J cells (3.5 ϫ 10 4 in 150 l antibiotic/fungizone-free DMEM containing 15% FBS) were added to each coated well. The cells were incubated for 1 day before the growth medium was replenished with 150 l serum-free DMEM, and the cells were serum starved for 20 -24 h before addition of gastrin (10 nM). The cells were grown for additionally 8 h after gastrin addition, before lysis in 20 l lysis buffer (Promega, Madison, WI). Luciferase activity was measured via the Dual-Luciferase Reporter Assay System (Promega) and Wallac 1420 Victor3 plate reader (Perkin Elmer, Boston, MA).
Assessment of apoptosis. Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was used to analyze apoptotic cells on a single cell level. Since AR42J cells grow in clusters, the cells were grown in wells coated with 4 l transfection mixture (96-well plate) as described above for reverse transfection (but without plasmid) to achieve a cell layer where AR42J cells could be separated from each other in single-cell analysis. AR42J cells (1.5 ϫ 10 4 in 150 l DMEM containing 15% FBS) were added to each coated well. The cells were incubated for 1 day before the growth medium was replenished with 150 l serum-free DMEM with or without gastrin (10 nM). The cells were further incubated for 72 h to induce apoptosis and assessed using the In Situ Cell Death Detection kit, fluorescein from Roche Diagnostics according to the manufacturer's descriptions. The nuclei were stained by incubating cells/well for 5 min with 50 l 0.1 g/ml 4=,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Invitrogen) in PBS. The percentage of apoptotic cells was determined by automated image acquisition of 25 images per well (ϫ10 magnification) using Scan^R Screening Station from Olympus (Hamburg, Germany) and automated image analysis using Scan^R Analysis software (1.3.0.3). In each independent experiment, ϳ20,000 -30,000 cells were counted per treatment.
Caspase activity was measured by using the Caspase-Glo 3/7 assay from Promega (Madison, WI) according to the manufacturer's descriptions. This is a luminescent assay that measures caspase-3 and -7 activities, and luminescence was measured via Wallac 1420 Victor3 plate reader (Perkin Elmer). The assay was performed as described for the TUNEL assay, except that AR42J cells were seeded out in white-walled 96-well plates (Perkin Elmer) without coating with transfection mixture. Antibodies (8 g/ml) were added at the time of gastrin treatment. Antibodies used: polyclonal (goat) anti-human clusterin-␣ and nonimmunized goat IgG.
Immunocytochemical staining. AR42J cells were seeded on Ultra-GAPS-coated slides (Corning, Corning, NY) with a cell culture accessory made of silicone (FlexiPERM from Vivascience, Göttingen, Germany) to achieve eight separate wells (10 5 cells in 200 l DMEM with 15% FBS per well). The cells were incubated for 1 day before the growth medium was replenished with 200 l serum-free DMEM, and the cells were serum starved for 24 h before gastrin addition (10 nM). Treated and untreated cells were grown in parallel. The protocol for immunofluorescence was based on Ref. 66 . Briefly, 17 h after adding gastrin, the cells were fixed (3.7% paraformaldehyde and 4% sucrose in PBS) for 20 min and permeabilized (0.1% Triton X-100 in PBS) for 15 min at room temperature. Furthermore, blocking was performed for 1 h (1.0% BSA in PBS), incubation with the primary (goat) anti-human clusterin-␣ polyclonal antibody diluted 1:50 in 0.5% BSA in PBS for 75 min, reblocking for 20 min, and incubation with secondary antibody [Alexa Fluor 488 (donkey) anti-goat diluted 1:1,000 in 0.5% BSA in PBS] for 1 h. The cell culture accessory was removed from the slide, and the nuclei were stained by incubating for 5 min with 500 l 0.1 g/ml DAPI (Invitrogen) in PBS per slide. The slide was mounted with Mowiol 4-88 mounting medium, pH 8.5, as described previously (17) , and placed at 4°C overnight before image acquisition. The stained samples were examined by confocal microscopy.
Immunohistochemistry. Fixed tissue samples were dehydrated, embedded in paraffin, and cut perpendicular to the mucosal surface in 4-m sections. Serial sections were mounted as mirrored pairs with their shared plane facing up. Before immunostaining, the sections were deparaffinized and rehydrated, and endogenous peroxidase activity was blocked with 3% H 2O2 for 10 min. Antigen retrieval was achieved by boiling in citrate-buffer pH 6.0 for 15 min. Clusterin was detected by using the primary (rabbit) anti-human clusterin polyclonal antibody (dilution 1:150) with incubation for 2 h at room temperature. Neuroendocrine cells in rats were detected by using the primary (rabbit) anti-porcine CgA polyclonal antibody (dilution 1:2,500) with incubation overnight at 4°C, and in five human histopathologically verified ECL cell carcinoids using the primary (mouse) anti-human CgA monoclonal antibody (dilution 1:4,000) with incubation for 1 h at room temperature. Further patient characteristics are described in Ref. 19 . The study protocol was approved by the Regional Committee for Medical Ethics. The ECL cells were detected by using the primary (rabbit) anti-HDC polyclonal antibody (dilution 1:3,000) with incubation for 2 h at room temperature. All immunoreactions were visualized by using the rabbit/mouse EnVision-HRP and DABϩ kit. Counterstaining was done with hematoxylin. Identical concentration of an isotype equivalent antibody from nonimmunized animals (rabbit polyclonal IgG) was used as negative control for the clusterin analysis.
Statistical analysis. All the data were log-transformed before statistical analysis. For presentation, the data were transformed back to original scale and plotted as means with 95% confidence interval as error bars. Student's t-test was used to evaluate statistical significance where indicated. For statistical analysis of the luciferase reporter gene assay and caspase assay, linear regression modeling was used as described previously (17) . For evaluating statistical significance, we performed a Bonferroni correction for multiple testing at 0.05 level in each analysis.
RESULTS

Gastrin increases expression of clusterin in adenocarcinoma cells.
Clusterin was initially identified as a gastrin-induced gene in AR42J cells by genomewide gene expression studies (Fig. 1A, top) . qRT-PCR analysis of three additional independent experiments (Fig. 1A, bottom) confirmed that gastrin increases clusterin mRNA levels 2-4 h after start of gastrin treatment, and the upregulation continued during the 12-14 h assayed. Our results show that even though the clusterin mRNA level is high in untreated AR42J cells (seen by the expression level in Fig. 1A, top) , the upregulation by gastrin is highly reproducible. Clusterin was also shown to be upregulated by gastrin on protein level from 4 -8 h after start of gastrin treatment (Fig. 1B) . Both the fully processed, mature secretory clusterin protein form (sCLU) and its uncleaved precursor (preCLU) were found upregulated by gastrin. The nuclear clusterin protein form (nCLU) may be present in AR42J cells, although we could not detect any increase in this ϳ50-kDa protein band after gastrin treatment. Our results show that the secreted form sCLU is the main clusterin protein form induced by gastrin in AR42J cells.
To further evaluate the clusterin protein forms present in AR42J cells, as well as the effect of gastrin on intracellular localization of clusterin, clusterin was assayed by immunocytochemistry of AR42J cells with and without gastrin treatment (Fig. 1C) . Clusterin was detected in the cytoplasm, with highest density close to the plasma membrane and in cytoplasmic protrusions. This supports the results from the Western blot analysis detecting mainly cytoplasmic clusterin protein forms. We could not detect increased amounts of clusterin in gastrintreated cells in the immunocytochemical analysis, possibly because of the high basal expression level of clusterin in these cells. Furthermore, no change in the intracellular localization of clusterin was observed in response to gastrin treatment.
Since gastrin was found to induce expression of sCLU (Fig.  1B) , we assessed whether gastrin treatment can lead to increased clusterin secretion. The ϳ40 kDa sCLU protein band was detected in conditioned medium from AR42J cells by Western blot analysis (Fig. 1D) , and the clusterin protein concentration was significantly increased at 12-24 h after start of gastrin treatment, as quantified by ELISA analysis (Fig. 1E) . Taken together, these results show that gastrin induces the expression and subsequent secretion of sCLU in AR42J cells.
We then investigated whether clusterin is directly induced by gastrin (primary response gene), or whether the induction is dependent on de novo protein synthesis (secondary response gene). Clusterin mRNA was measured in gastrin-treated cells in the absence or presence of the protein synthesis inhibitor CHX. As shown in Fig. 2A (top, microarray data; bottom, qRT-PCR data), clusterin mRNA level is increased by gastrin in the presence of CHX, indicating that clusterin is upregulated by gastrin independently of de novo protein synthesis. Thus our results indicate that even though there is a lag of 2-4 h before a rise in clusterin mRNA is detectable in response to gastrin treatment, clusterin is clearly a primary response gene that can be induced by gastrin by posttranslational activation of intracellular signaling components already present in the cell. However, the increase in clusterin mRNA was lower in the presence of CHX ( Fig. 2A) , indicating that, to achieve maximal expression of clusterin in response to gastrin, de novo protein synthesis of one or several components in the signaling pathways from the gastrin/CCK-2 receptor to the activation of the clusterin promoter has to occur.
The clusterin promoter contains several different promoter elements, including the AP-1 element (49, 62) , which mediates the transcriptional activation from the AP-1 transcription factor complex composed of Jun and Fos proteins. Several other reports have shown that regulation of clusterin expression is mediated through AP-1, including activation of clusterin expression by TGF-␤ (26, 27) . We (Ref. 53 and unpublished data), as well as others (55) , have shown that gastrin induces expression of genes encoding members of the AP-1 complex, like c-fos and junB. To investigate AP-1 as a possible mediator of gastrin-induced expression of clusterin, AR42J cells were transfected with reporter plasmids containing the luciferase gene driven by the rat clusterin promoter with or without the AP-1 site. A plasmid with a minimal TATA promoter was used as negative control. Gastrin treatment increased the luciferase expression only in cells transfected with the plasmid containing the intact clusterin promoter (Fig. 2B) , demonstrating that the presence of AP-1 promoter element is necessary for gastrininduced activation of clusterin reporter plasmid. This indicates a role for the AP-1 transcription factor complex in activation of clusterin transcription by gastrin.
Duration of a hormonal signal can influence transcriptional output (20) and cell fate (41) . Therefore, we assessed the effect of gastrin signal duration on the induction of clusterin expres-sion. AR42J cells were subjected to sustained gastrin treatment (continuous treatment for 14 h) or transient gastrin treatment (gastrin removed after 1 h). The clusterin mRNA and protein levels in transiently treated cells were similar to the levels in untreated cells (Fig. 3, A and B) . Similarly, a lack of increase in clusterin mRNA expression was also observed when the gastrin stimulant was maintained for 2 h before removal (microarray data, data not shown, accession number: E-MTAB-123). In addition, increased levels of secreted clusterin were only observed with sustained gastrin treatment (Fig. 3C) . Our results indicate that the duration of gastrin treatment must exceed 2 h to induce clusterin expression as well as increased levels of secreted clusterin. This observation is highly interesting in light of the known prosurvival effect of sCLU (51) and the fact that high levels of gastrin over prolonged time periods, hypergastrinemia, is known to have a trophic effect on the gastric mucosa (59).
Neutralization of secreted clusterin abolishes the antiapoptotic effect of gastrin in adenocarcinoma cells.
Since sCLU has been shown to have prosurvival effects (51), we hypothesized that clusterin is involved in gastrin's antiapoptotic function (56) . We induced apoptosis in AR42J cells by serum starvation for 72 h and cultivated the cells in the absence or presence of gastrin. Apoptotic cells were visualized using TUNEL assay, and the fraction of apoptotic cells was quantified using automated microscopy and image analysis. The result showed a significant antiapoptotic effect of gastrin, with ϳ2.4% apoptotic cells in the absence of gastrin and ϳ0.3% apoptotic cells in the presence of gastrin (Fig. 4A) . The antiapoptotic effect was confirmed using the Caspase-Glo 3/7 assay, showing a 40% reduction in effector caspase activity in the presence of gastrin (data not shown).
Since clusterin is described as a stress-induced gene (51), we tested whether serum starvation for 72 h in itself can increase the expression and secretion of clusterin. Untreated and gastrin-treated AR42J cells were grown in medium with or without serum for 72 h, and the amount of clusterin protein was analyzed in whole-cell lysates by Western blot analysis (Fig.  4B ) and in conditioned medium by ELISA analysis (Fig. 4C) . Serum starvation for 72 h did not increase the expression or secretion of clusterin in the absence of gastrin. In addition, 72 h of gastrin treatment increased the expression and secretion of clusterin both in the presence and absence of serum. However, the effect of gastrin was less in the presence of serum, possibly because of inhibitory factors in serum. Taken together, the results show that clusterin persists at high levels, both intracellularly and extracellularly, after 72 h of gastrin treatment.
To examine whether the gastrin-induced increased levels of secreted clusterin can play a role in the antiapoptotic effect of gastrin, we investigated the effect of gastrin on serum starvation-induced apoptosis in the absence or presence of a clusterin antibody (C-18), which has been reported by others to inhibit clusterin function (36) . In the presence of nonimmunized IgG, gastrin treatment resulted in decreased caspase activity (Fig.  4D) , again confirming the antiapoptotic effect of gastrin. In the presence of clusterin antibody, no significant decrease in caspase activity was found after gastrin treatment, showing that the clusterin antibody blocked the antiapoptotic effect of gastrin. Taken together, our results suggest that secreted clusterin is involved in the antiapoptotic effect of gastrin.
Hypergastrinemia in rats increases clusterin in the oxyntic mucosa and in plasma.
To validate the clusterin response to gastrin in an in vivo model, we addressed whether the level of clusterin expression was increased in oxyntic mucosa of hypergastrinemic rats compared with control rats. The proton pump inhibitor pantoprazole was used to induce hypergastrinemia for either 1 or 4 wk, of which some of the 1 wk rats also received the gastrin/CCK-2 receptor antagonist YF476. The plasma gastrin concentration was 22.6 Ϯ 5.8 pM (mean Ϯ SE, n ϭ 24) in control rats and increased by pantoprazole dosing to 208.9 Ϯ 16.6 pM (mean Ϯ SE, n ϭ 15) after 1 wk, 250.3 Ϯ 28.8 pM (mean Ϯ SE, n ϭ 9) after 4 wk, and 258.5 Ϯ 61.6 pM (mean Ϯ SE, n ϭ 6) after 1 wk coadministration with YF476. qRT-PCR analysis was used to measure clusterin mRNA in control rats and hypergastrinemic rats, without or with concomitant YF476 (Fig. 5, A and B) . Clusterin mRNA levels were significantly increased in the oxyntic mucosa of rats hypergastrinemic for both 1 and 4 wk, and concomitant gastrin antagonism significantly reduced the clusterin mRNA levels. Western blot analysis showed that sCLU was increased in the oxyntic mucosa of rats hypergastrinemic for 4 wk (Fig. 5C) .
Since we observed a significant increase in secreted clusterin from gastrin-treated AR42J cells (Fig. 1E) , and the secreted clusterin protein form was found upregulated in oxyntic mucosa of hypergastrinemic rats (Fig. 5C) , we assessed the plasma levels of clusterin in hypergastrinemic (n ϭ 9 1 wk, n ϭ 9 4 wk) and control (n ϭ 18) rats. Significantly elevated levels of clusterin in plasma of hypergastrinemic rats were found by ELISA analysis, with no difference between 1 and 4 wk of hypergastrinemia (Fig. 5D) . These results indicate that gastrin increases the expression of clusterin mRNA and protein in the rat oxyntic mucosa, as well as secretion to the plasma.
To further investigate the possible biological function of clusterin in the oxyntic mucosa, immunohistochemistry was used to examine the localization of clusterin-immunoreactive , where the AP-1-binding site in the promoter is deleted, or a control plasmid with a minimal TATA promoter (pTA-Luc). Cotransfection with phRL-Null was performed for normalization. The cells were grown in the absence or presence of gastrin for 8 h prior to measurement of Firefly luciferase activity normalized to Renilla luciferase activity. Relative luciferase activity was estimated by linear regression modeling (17) using data from 3 independent experiments (6 -19 technical replicates in each independent experiment), normalizing the data to the median intensity of untreated cells transfected with pTA-Luc in each independent experiment. Error bars represent 95% CI. *Bonferroni-adjusted P value Ͻ0.05; significant difference from untreated cells by Student's t-tests.
cells. In mucosa of control rats, strong clusterin immunoreactivity was found in scattered single cells throughout the gastric glands, but predominantly in the basal half of the glands. There also seemed to be some clusterin immunoreactivity in most of the other epithelial cells, although with clearly lower and more heterogeneous intensity. The intracellular localization was primarily cytoplasmic and granular, but nuclear staining was also seen. The cells with strongest immunoreactivity were of relatively small size, situated between the epithelial cells of the glands and with shapes suggesting cytoplasmatic protrusions running both along the basal side of the epithelial cells and toward the lumen of the glands (Fig. 6, A and B) . Thus their low number, distribution, and appearance suggested that they were neuroendocrine cells. The stromal compartment of the oxyntic mucosa and submucosa did not show obvious immunoreactivity for clusterin.
In hypergastrinemic oxyntic mucosa the number and distribution of cells with strong clusterin immunoreactivity were different compared with control rats. In addition to the scattered single cells along the lower half of the glands seen in controls, the base of many glands showed strong clusterin immunoreactivity in all cell types. These groups of strongly clusterin-immunoreactive cells had varying heights and in some of them varying intensity of clusterin immunoreactivity, showing scattered cells within the groups with stronger intensity (Fig. 6, C-F) . A few such basal groups of clusterin immunoreactivity were also observed in mucosa of control rats (Fig. 6A ). There was no obvious difference between the patterns in mucosa of rats hypergastrinemic for 1 wk or 4 wk. The total number of cells with strong clusterin immunoreactivity seemed to be greater in mucosa of both hypergastrinemic groups compared with control. Immunohistochemistry was performed on sections from five different animals from each group, all showing similar results. Replacing the clusterin antibody with negative control gave no immunoreactivity. To confirm the observed clusterin immunoreactivity pattern, the staining was repeated with another antibody (C-18), and this yielded similar results (data not shown).
To further examine the hypothesis that the scattered cells with strong clusterin immunoreactivity were neuroendocrine cells, serial sectioning was done on samples from two control rats and two hypergastrinemic rats (4 wk). Immunohistochemistry for the neuroendocrine marker CgA or clusterin on consecutive sections was performed, showing nearly complete overlap in mucosa of control rats (Fig. 7, A-D) . This indicates that, in normal oxyntic mucosa, clusterin is strongly expressed in at least a vast majority of the CgA-immunoreactive neuroendocrine cells. In hypergastrinemic rats, there was less obvious correlation between clusterin and CgA immunoreactivity. In some of the glands filled with clusterin-immunoreactive cells, corresponding CgA-immunoreactive cells could be distinguished. However, some CgA-immunoreactive cells were not clusterin immunoreactive and vice versa (Fig. 7,   Fig. 3 . Increased clusterin expression is dependent on sustained gastrin stimulation. AR42J cells were grown in the absence (untreated, U) or in the presence of gastrin in a sustained (S) mode (continuous presence of gastrin) or a transient (T) mode (gastrin removed after 1 h of treatment). A: clusterin mRNA measured by microarray gene expression analysis (accession number: GSE32869) and qRT-PCR analysis. Each dot per time point represents 1 independent experiment. Expression levels relative to untreated cells (microarray data), or relative to time point zero (qRT-PCR data; B2m as reference gene). B: clusterin protein in whole-cell lysates assayed by Western blot analysis. A representative image is shown together with quantification of sCLU bands from 3 independent experiments. Mean intensities relative to time point zero. Error bars represent 95% CI. C: clusterin protein in conditioned medium quantified by ELISA. Mean of 3 independent experiments. Error bars represent 95% CI. *Bonferroni-adjusted P value Ͻ0.05; significant difference from untreated cells at the same time point by Student's t-tests.
E-H).
To specify the neuroendocrine cells in which clusterin were localized, staining of consecutive serial sections with the ECL cell specific marker HDC and clusterin was done in control rat, showing nearly complete cellular colocalization between HDC and clusterin immunoreactivities (Fig. 7, I and J). This demonstrates that the main clusterin-immunoreactive neuroendocrine cell type in normal mucosa is indeed the ECL cell. To further address the neuroendocrine localization, immunohistochemistry on histopathologically verified gastric ECL carcinoids from five patients with hypergastrinemia due to chronic atrophic gastritis and pernicious anemia (19) was performed. The result showed strong immunoreactivity in a subset of the CgA-immunoreactive cells of the tumors, with no detectable positivity in nonneuroendocrine cells outside the tumors (Fig. 7, K and L) . Taken together, these results show that clusterin is normally strongly expressed by neuroendocrine cells in the oxyntic mucosa, of which most are ECL cells, whereas hypergastrinemia seems to induce additional clusterin immunoreactivity in all cell types at the base of many glands.
DISCUSSION
In the present study we have shown that sustained gastrin treatment increases clusterin mRNA and protein expression, followed by a significant increase in secretion of the prosurvival sCLU in adenocarcinoma AR42J cells. Our results indicate that gastrin activates the clusterin gene via signal transduction pathways involving the AP-1 transcription factor complex and that clusterin is a primary gastrin response gene, since increased clusterin gene expression occurs independently of de novo protein synthesis. The clusterin promoter includes several other binding sites than AP-1 (49, 62), and more thorough . Relative caspase activity was estimated by linear regression modeling (17) using data from 3 independent experiments (2-6 technical replicates in each independent experiment), normalizing the data to the median intensity of untreated cells with nonimmunized IgG in each independent experiment. Error bars represent 95% CI. *Bonferroni-adjusted P value Ͻ0.05; significant difference from untreated cells by Student's t-test. studies will be needed to determine all the molecular mechanisms involved in the signaling pathways from gastrin activation of the gastrin/CCK2 receptor to the induction of clusterin expression.
Gastrin-induced clusterin expression and subsequent secretion is functionally important for the cellular responses to gastrin, since neutralization of secreted clusterin abolished the antiapoptotic effect of gastrin on serum starvation-induced apoptosis. The clusterin response to gastrin was validated in vivo in hypergastrinemic rats showing increased levels of clusterin mRNA and the sCLU protein form in oxyntic mucosa, as well as higher levels of circulating clusterin proteins in plasma. The response was significantly reduced by simultaneous gastrin antagonism. On the basis of our results, we argue that the responses in hypergastrinemic oxyntic mucosa are also most probably due to gastrin stimulation. Removal of gastrin after 1-2 h abolished gastrin-induced expression and subsequent secretion of clusterin in AR42J cells, indicating that gastrin-mediated induction of clusterin expression is dependent on sustained gastrin treatment. This has interesting implications for gastrin biology and pathobiology, since it may indicate that clusterin mainly plays a role in the gastrin response under conditions with prolonged high levels of gastrin in the oxyntic mucosa.
In normal oxyntic mucosa, we found a nearly complete overlap between the strong clusterin-immunoreactive cells and CgA-immunoreactive neuroendocrine cells. Further specification demonstrated that most of the clusterin-expressing neuroendocrine cells were ECL cells, since nearly all HDC immunoreactivity colocalized with clusterin-immunoreactive cells. Clusterin association with neuroendocrine differentiation was also confirmed by strong clusterin immunoreactivity in a subset of the CgA-immunoreactive cells of a gastric ECL carcinoid, with no detectable positivity in nonneuroendocrine cells outside the tumor. These findings are in accordance with several previous reports on the detection of clusterin protein in neuroendocrine cells of colon (2), pancreas (40) , adenohypophysis (11, 14) , and the pheochromocytoma cell line PC12 (4). The localization of clusterin mRNA in the gastrointestinal tract and many other tissues in mice has previously been investigated, showing clusterin mRNA to be localized mainly in epithelial cells and other secreting cells (5) , which is in agreement with our results. In the stomach, cells containing clusterin mRNA were judged by the authors to be chief cells. However, this study did not apply specific methods to identify neuroendocrine cells. The ECL cells dominate the neuroendocrine cell population in the rat oxyntic mucosa. These cells are known to possess the gastrin/CCK-2 receptor (8) and to be important Fig. 5 . Clusterin is upregulated in oxyntic mucosa and in plasma of hypergastrinemic rats. A: clusterin mRNA level in rat oxyntic mucosa from control rats (n ϭ 6) and rats hypergastrinemic for 1 wk in the absence (n ϭ 6) or presence (n ϭ 6) of the gastrin/ CCK-2 receptor antagonist YF476 assayed by qRT-PCR analysis (B2m as reference gene). B: clusterin mRNA level in rat oxyntic mucosa from control rats (n ϭ 5) and rats hypergastrinemic for 4 wk (n ϭ 5) assayed by qRT-PCR analysis (B2m as reference gene). C: clusterin protein in oxyntic mucosa from control rats (n ϭ 5) and rats hypergastrinemic for 4 wk (n ϭ 5) assayed by Western blot analysis. The sCLU bands were quantified and are shown as dots in the figure. The medians are indicated with horizontal lines. D: clusterin protein in plasma from control rats (n ϭ 18) and rats hypergastrinemic for 1 wk (n ϭ 9) and 4 wk (n ϭ 9) quantified by ELISA analysis. Statistical significance was evaluated by Student's ttests. *Bonferroni-adjusted P value Ͻ0.05. target cells for gastrin, which regulates both their function and growth (7) . In a previous gene expression study, examining the molecular mechanisms underlying the antiproliferative effect of the somatostatin analog octreotide on the oxyntic mucosa, clusterin was found to be downregulated and there was a tendency toward increased apoptosis and decreased proliferation in the mucosa (15) . Somatostatin is a general inhibitor in the gastrointestinal tract and particularly of the ECL cells (9) . Thus this finding is in agreement with our results strongly suggesting ECL cells as the initial main clusterin expressing cell in the oxyntic mucosa responsible for the increased production of clusterin by gastrin.
In hypergastrinemic rats, we observed an additional strong clusterin immunoreactivity in all cell types at the base of many glands, where clusterin-immunoreactive cells form distinct groups. Thus contrary to the situation in normal oxyntic mucosa, clusterin was now also present in several different cell types other than the CgA-immunoreactive neuroendocrine cells. Still, it was possible to distinguish intensely clusterin stained cells in the basal groups corresponding to the CgAstained cells in mirrored sections, although there was in general less correlation between CgA and clusterin-immunoreactive cells than in normal oxyntic mucosa. It is unlikely that all the cells in the groups of clusterin-immunoreactive cells in hypergastrinemic oxyntic mucosa express the gastrin/CCK-2 receptor. One possible mechanism underlying the presence of clusterin in nonneuroendocrine cells devoid of gastrin/CCK-2 receptor may be related to paracrine mediators, which can be secreted from ECL cells in response to gastrin (25) , and which may thus induce increased expression of clusterin in neighboring cells. In addition, it has been suggested that clusterin may be reinternalized from the extracellular milieu into the cytosol (29, 57) . Thus another possibility may be that clusterin, produced and secreted by ECL cells in response to gastrin, is transported to the interstitium, from which it is subsequently taken up by neighboring cells. Indeed, we found increased levels of clusterin in plasma of hypergastrinemic rats, strongly suggesting that gastrin increases secretion of clusterin that may then be available for uptake by nonneuroendocrine cells in the gastric mucosa. Depletion of clusterin from the ECL cells below the detection limit of immunohistochemistry because of secretion could also be an explanation for the less obvious correlation between clusterin and CgA-immunoreactive cells in hypergastrinemic mucosa.
The functional role of gastrin-induced clusterin was addressed in our in vitro model, AR42J cells, where our results strongly indicate that extracellular clusterin is involved in gastrin-mediated inhibition of apoptosis. Others have also described clusterin to have a prosurvival effect in AR42J cells (50) , and gastrin has previously been shown to have an antiapoptotic effect in AR42J cells (47, 54, 56) and in other transformed cells (23, 24, 33, 45) . Hypergastrinemia is found to be associated with increased expression of antiapoptotic genes and decreased expression of proapoptotic genes in both human (43) and rat (44) oxyntic mucosa. Gastrin has been shown to increase the expression of antiapoptotic genes also in rat ECL cells (18) . In agreement of the latter, the results of Mahr et al. (39) indicate that gastrin may have a direct antiapoptotic effect on ECL cells, although their results were not statistically significant. On the basis of our observation on the central role of clusterin as a mediator of gastrin's antiapoptotic effect in AR42J adenocarcinoma cells in culture, we suggest that clusterin may play a role in mediating an antiapoptotic effect also in the gastric mucosa.
The mechanisms underlying the role of extracellular clusterin in the antiapoptotic effect of gastrin are most likely linked to its ability to bind to a broad spectrum of hydrophobic molecules on one hand and to specific cell-surface receptors on the other hand (32) . Secreted clusterin is one of the first described extracellular chaperones and binds to misfolded and denatured proteins to keep them in solution, thereby inhibiting aggregation and precipitation. Clusterin has therefore been suggested to be part of an extracellular quality control system of protein folding that also includes receptor-mediated endocytosis and lysosomal degradation of extracellular misfolded proteins (61, 63, 65) . Indeed, clusterin has been found to interact with endocytic receptors, such as megalin (gp330, LPR-2), and to mediate endocytosis and lysosomal degradation of potentially harmful extracellular molecules, such as hydrophobic, denatured, and aggregated molecules, cellular debris, and apoptotic bodies, from the extracellular space (6, 10, 22, 34). Therefore, we speculate that one of the mechanisms by which clusterin mediates the antiapoptotic effect of gastrin may involve removal of harmful molecules present in the extracellular space. In addition, recent work indicates that secreted clusterin may modulate intracellular signal transduction pathways by binding to receptors or by inhibiting ligands from binding to their receptors (1, 28, 52) . Thus secreted clusterin may also mediate or enhance gastrin-induced protection of cells from apoptotic stimuli by modulating intracellular signal transduction pathways. Although we have shown that neutralization of clusterin extracellularly abolished the antiapoptotic effect of gastrin in AR42J cells, clusterin in the cytoplasm has been reported to interact with intracellular molecules, and may thus have functional roles in the gastrin response. For examples, clusterin has been reported to inhibit Bax-induced apoptosis by stabilizing the cytosolic ku70-Bax protein complex (58) and has also been suggested to function as an endoplasmic reticulum chaperone (42) .
In conclusion, we have shown that gastrin induces the expression of the prosurvival sCLU protein in a gastrin/ CCK-2 receptor expressing adenocarcinoma cell line and in oxyntic mucosa of hypergastrinemic rats. At least in the basal state, our results suggest ECL cells as the main clusterin expressing cell in the rat oxyntic mucosa. In hypergastrinemic mucosa additional clusterin immunoreactivity was observed in distinct groups of diverse cells at the base of many glands. Our results indicate further that clusterin plays a role in the antiapoptotic action of gastrin and therefore may be important in the growth-promoting effect of gastrin on the oxyntic mucosa. 
